What's Happening?
Smith+Nephew, a global medical technology company, has launched the CENTRIO Platelet-Rich-Plasma (PRP) System in the United States. This system is a biodynamic hematogel derived from a patient's own platelets and plasma, designed to assist the natural healing process by maintaining a moist wound environment. The CENTRIO PRP System is intended for managing chronic exuding wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and tunneling wounds. The system is designed for point-of-care use in both hospital and physician office settings, and can be tailored to fit wound shape, depth, and stage with a single draw of a patient's blood. The system has demonstrated efficacy in clinical trials, making it a strong addition to Smith+Nephew's portfolio.
Why It's Important?
The launch of the CENTRIO PRP System represents a significant advancement in wound care technology, offering a new solution for managing chronic wounds that are difficult to heal. With CMS coverage for autologous PRP in treating chronic non-healing wounds for diabetic patients, the system is poised to improve patient outcomes and ease the burden of living with hard-to-heal wounds. The system's introduction aligns with Smith+Nephew's strategy to expand access to innovative and clinically proven biological solutions, enhancing its position in the advanced wound management market.
What's Next?
The CENTRIO PRP System will be showcased at the Smith+Nephew booth during the Symposium on Advanced Wound Care Fall Conference in Las Vegas, Nevada. Smith+Nephew has entered into an exclusive private label distribution agreement with Nuo Therapeutics Inc. to market the system in the United States. The company aims to continue expanding its portfolio of proven biological solutions to augment healing outcomes backed by extensive clinical evidence.
